Levi & Korsinsky reminds Intellia investors of pending class action lawsuit
Investors in Intellia Therapeutics (NTLA) need to be aware of an impending class-action lawsuit. Levi & Korsinsky, a securities litigation firm, is reminding investors about the lawsuit with a lead plaintiff deadline of April 14, 2025. The lawsuit focuses on whether Intellia and its executives have violated federal securities laws.
The class-action lawsuit alleges that Intellia made false and misleading statements regarding the ability of its CRISPR technology to safely and effectively edit genes in patients. The lawsuit claims that the company exaggerated the efficacy and safety of its technology, leading to artificially inflated stock prices. When the truth about the limitations and risks of Intellia’s technology came to light, the stock prices plummeted, causing financial harm to investors.
Investors who purchased Intellia securities between April 11, 2019, and February 12, 2022, may be eligible to participate in the class-action lawsuit. The lead plaintiff deadline is fast approaching on April 14, 2025. Investors must act quickly to ensure they are included in any potential recovery.
It is essential for investors who believe they may have suffered financial losses due to investing in Intellia securities to contact Levi & Korsinsky promptly. The firm specializes in securities litigation and has a proven track record of recovering losses for investors who have been misled by companies and their executives.
If you are an investor in Intellia Therapeutics and believe you may have a claim in the pending class-action lawsuit, it is crucial to act now. Contact Levi & Korsinsky before the lead plaintiff deadline of April 14, 2025, to ensure you are included in any potential recovery. Don’t delay in seeking the compensation you may be entitled to as a result of the alleged securities law violations by Intellia and its executives.
